Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis

Li,Yang; Guo,Xiao‑Bo; Wang,Jin  Shen; Wang,Hong‑Chang; Li,Le‑Ping

doi:10.3892/mmr.2019.10850

Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis

Authors:
- Yang Li
- Xiao‑Bo Guo
- Jin Shen Wang
- Hong‑Chang Wang
- Le‑Ping Li
View Affiliations

Affiliations: Gastrointestinal Department of Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250000, P.R. China
Published online on: November 26, 2019 https://doi.org/10.3892/mmr.2019.10850
Pages: 575-582
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the role of fibroblast growth factor 2 (FGF2) in the development and prognosis of gastric cancer (GC). The relationship between FGF2 mRNA expression levels and the clinical characteristics of GC was investigated using microarray data from four GC cohorts involving 726 patients obtained from the Gene Expression Omnibus. The results of the present study indicated that FGF2 expression levels were an independent factor affecting the prognosis of GC. The primary functions of FGF2 were related to cell adhesion and angiogenesis, and patients with high levels of FGF2 expression had poorer TNM staging and prognosis; these differences were statistically significant. In terms of immune infiltration, a higher extent of M2 macrophage intrusion was observed in patients with higher levels of FGF2. However, the degree of infiltration by dendritic and CD4+ T cells was lower, and this difference was statistically significant. Multivariate Cox proportional hazards model analysis revealed that age, TNM staging and FGF2 expression levels were independent prognostic factors for GC. In summary, FGF2 expression was demonstrated to be an independent prognostic factor in GC, and higher levels of FGF2 may promote the progression of this malignancy.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jung KW, Won YJ, Kong HJ, Oh CM, Shin A and Lee JS: Survival of korean adult cancer patients by stage at diagnosis, 2006–2010: National cancer registry study. Cancer Res Treat. 45:162–171. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lee JY, Cho KB, Kim ES, Park KS, Lee YJ, Lee YS, Jang BK, Chung WJ and Hwang JS: Risk factors for local recurrence after en bloc endoscopic submucosal dissection for early gastric cancer. World J Gastrointest Endosc. 8:330–337. 2016. View Article : Google Scholar : PubMed/NCBI
4	Lu Y, Xu Q, Zuo Y, Liu L, Liu S, Chen L, Wang K, Lei Y, Zhao X and Li Y: Isoprenaline/β2-AR activates plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer. 17:8752017. View Article : Google Scholar : PubMed/NCBI
5	Xie M, Dart DA, Guo T, Xing XF, Cheng XJ, Du H, Jiang WG, Wen XZ and Ji JF: MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer. Gastric Cancer. 21:41–54. 2018. View Article : Google Scholar : PubMed/NCBI
6	D'Angelo G, Di Rienzo T and Ojetti V: Microarray analysis in gastric cancer: A review. World J Gastroenterol. 20:11972–11976. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hitzemann R, Bottomly D, Darakjian P, Walter N, Iancu O, Searles R, Wilmot B and McWeeney S: Genes, behavior and next-generation RNA sequencing. Genes Brain Behav. 12:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
8	Moffett J, Kratz E, Florkiewicz R and Stachowiak MK: Promoter regions involved in density-dependent regulation of basic fibroblast growth factor gene expression in human astrocytic cells. Proc Natl Acad Sci USA. 93:2470–2475. 1996. View Article : Google Scholar : PubMed/NCBI
9	Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM and Grose RP: Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med. 6:467–481. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ren T, Qing Y, Dai N, Li M, Qian C, Yang Y, Cheng Y, Li Z, Zhang S, Zhong Z and Wang D: Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci. 105:186–194. 2014. View Article : Google Scholar : PubMed/NCBI
11	Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L, Lu K, Tao T, Zhang X and Huang Y: miR-195 inhibits EMT by targeting FGF2 in prostate cancer cells. PLoS One. 10:e01440732015. View Article : Google Scholar : PubMed/NCBI
12	Kim SK and Hebrok M: Intercellular signals regulating pancreas development and function. Genes Dev. 15:111–127. 2001. View Article : Google Scholar : PubMed/NCBI
13	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
14	Clarke WE, Berry M, Smith C, Kent A and Logan A: Coordination of fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor-2 (FGF-2) trafficking to nuclei of reactive astrocytes around cerebral lesions in adult rats. Mol Cell Neurosci. 17:17–30. 2001. View Article : Google Scholar : PubMed/NCBI
15	Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al: Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 5:e10006762009. View Article : Google Scholar : PubMed/NCBI
17	Qian Z, Zhu G, Tang L, Wang M, Zhang L, Fu J, Huang C, Fan S, Sun Y, Lv J, et al: Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. Genes Chromosomes Cancer. 53:883–894. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, et al: Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 145:554–565. 2013. View Article : Google Scholar : PubMed/NCBI
19	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
20	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
21	Berlth F, Bollschweiler E, Drebber U, Hoelscher AH and Moenig S: Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol. 20:5679–5684. 2014. View Article : Google Scholar : PubMed/NCBI
22	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kamarudin AN, Cox T and Kolamunnage-Dona R: Time-dependent ROC curve analysis in medical research: Current methods and applications. BMC Med Res Methodol. 17:532017. View Article : Google Scholar : PubMed/NCBI
24	Cho JY: Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer. 13:129–135. 2013. View Article : Google Scholar : PubMed/NCBI
25	Guzy RD, Stoilov I, Elton TJ, Mecham RP and Ornitz DM: Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin. Am J Respir Cell Mol Biol. 52:116–128. 2015. View Article : Google Scholar : PubMed/NCBI
26	Ferreras C, Rushton G, Cole CL, Babur M, Telfer BA, van Kuppevelt TH, Gardiner JM, Williams KJ, Jayson GC and Avizienyte E: Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor. J Biol Chem. 287:36132–36146. 2012. View Article : Google Scholar : PubMed/NCBI
27	Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, et al: Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis. 38:1073–1083. 2017. View Article : Google Scholar : PubMed/NCBI
28	Lau MT, So WK and Leung PCK: Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 8:e590832013. View Article : Google Scholar : PubMed/NCBI
29	He Q, Ren X, Chen J, Li Y, Tang X, Wen X, Yang X, Zhang J, Wang Y, Ma J and Liu N: miR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways. Oncotarget. 7:3047–3058. 2016.PubMed/NCBI
30	Choi YY, Jang E, Seo WJ, Son T, Kim HI, Kim H, Hyung WJ, Huh YM, Noh SH and Cheong JH: Modification of the TNM staging system for stage II/III gastric cancer based on a prognostic single patient classifier algorithm. J Gastric Cancer. 18:142–151. 2018. View Article : Google Scholar : PubMed/NCBI
31	Boeker M, França F, Bronsert P and Schulz S: TNM-O: Ontology support for staging of malignant tumours. J Biomed Semantics. 7:642016. View Article : Google Scholar : PubMed/NCBI
32	Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, et al: Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. OncoImmunology. 5:e10545982015. View Article : Google Scholar : PubMed/NCBI
33	Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL and Kim WH: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 99:1704–1711. 2008. View Article : Google Scholar : PubMed/NCBI
34	Zhang WJ, Zhou ZH, Guo M, Yang LQ, Xu YY, Pang TH, Gao ST, Xu XY, Sun Q, Feng M, et al: High infiltration of polarized CD163+tumor-associated macrophages correlates with aberrant expressions of CSCs markers, and predicts prognosis in patients with recurrent gastric cancer. J Cancer. 8:363–370. 2017. View Article : Google Scholar : PubMed/NCBI
35	Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al: Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 232:199–209. 2014. View Article : Google Scholar : PubMed/NCBI
36	Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
37	Sun HW, Tang QB, Cheng YJ and Zou SQ: Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response. World J Gastroenterol. 10:2595–2597. 2004. View Article : Google Scholar : PubMed/NCBI
38	He S, Wang L, Wu Y, Li D and Zhang Y: CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J Exp Clin Cancer Res. 29:372010. View Article : Google Scholar : PubMed/NCBI
39	Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, et al: Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer. Oncol Rep. 37:3341–3350. 2017. View Article : Google Scholar : PubMed/NCBI
40	Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, et al: Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer. 19:1052–1065. 2016. View Article : Google Scholar : PubMed/NCBI
41	Yuan L, Xu B, Yuan P, Zhou J, Qin P, Han L, Chen G, Wang Z, Run Z, Zhao P and Gao Q: Tumor-infiltrating CD4⁺ T cells in patients with gastric cancer. Cancer Cell Int. 17:1142017. View Article : Google Scholar : PubMed/NCBI